CMN Weekly (20 December 2024) - Your Weekly CRISPR...
CMN Weekly
Dec. 20, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Capstan Therapeutics
Company Type: Therapeutic development
Main focus: Developing treatments for various diseases through engineering immune cells and targeting pathogenic cells with mRNA-encoded gene-editing technology
Company stage: Pre-clinical
Diseases: Cancer, autoimmune disorders, fibrosis, and monogenic blood disorders
Genome-editing tool: mRNA-encoded gene editing machinery
Funding stage: Series B
Location: San Diego, California, USA
Website: https://www.capstantx.com/
Pipeline:
Partners:
Capstan Therapeutics is a biotechnology company dedicated to advancing new therapies through targeted and precise in vivo gene- and cell engineering. Their approach to disease treatments follows two distinct pathways; engineering immune cells and targeting pathogenic cells through in vivo gene editing. Capstan’s core technology revolves around targeted lipid nanoparticles (tLNPs) carrying disease-specific payloads.
